Oncopeptides Ab · OMXSTO:ONCO
Oncopeptides Ab — Q1 2025 Earnings Presentation
29 slides from Oncopeptides Ab's earnings presentation, May 15, 2025
Slide 1: Q1 Report 2025
Q1 REPORT 2025 May 15, 2025 1
Slide 2: Important: You must read the following before continuing
© oncopeptides 25 years IMPORTANT: You must read the following before continuing. The following applies to this document, the oral presentation of the information in this document by Oncopeptides AB (the “Company”) or any person on behalf of the Company, and any question-and-answer session that foll
Slide 3: Presenters
PRESENTERS Sofia Heigis Henrik Bergentoft CEO CFO 3
Slide 4: Where we are right now
WHERE WE ARE RIGHT NOW FINANCIALS HIGHLIGHTS EVENTS JANUARY-MARCH • Net sales of SEK 13.3m in Q1 2025 • Oncopeptides announces that the positive reimbursement decision for Pepaxti has been officially (SEK 5.1m in Q1 published in Italy. This marks the final regulatory step for the drug´s upcoming
Slide 5: Financial update
FINANCIAL UPDATE Henrik Bergentoft Chief Financial Officer 5
Slide 6: Financial summary
Financial summary MSEK Jan-Mar Jan-Mar Jan-Dec Jan-Dec• 34% sales growth 2025 2024 2024 2023 compared to Q4 Net sales 13.3 5.1 31.6 35.2 2024 and 160% COGS 0.1 -0.3 -2.7 1.1 compared to Q1 13.4 4.8 29.0 36.3 2024. Gross profit Expenses -74.0 -74.0 -318.5 -295.4 • Operating Other operating 0.8 3.5 5.
Slide 7: Operating expenses
Operating expenses MSEK 120 • S&M cost increased from 27.7 MSEK in Q1 -24 to 28.5 MSEK in Q1 -25. 100 • Organization in Spain and Germany were finalized during 2024 and in Q1 2025 the 74 Italian organization is in place. 80 MSEK 74 MSEK • G&A cost decreased from 17.9 to 16.8 MSEK, mainly due to cost
Slide 8: Liquidity
Liquidity MSEK 450 400 • Cash was 107 MSEK at end of Q1. 350 • Cash position in line with 300 expectations. 250 • Liquidity position after rights issue estimated to last until 200 107 MSEK cash flow positive end of 2026 – requiring continued sales 150 growth and concluded partnership in Japan. 100 •
Slide 9: Commercial update
COMMERCIAL UPDATE Sofia Heigis Chief Executive Officer 9
Slide 10: Drivers of European growth in Q1 2025 and moving toward profitability end 2026
Drivers of European growth in Q1 2025 and onwards moving toward profitability end 2026 ✓ Innovative price negotiated in Germany, Austria, ✓ Increased positive clinical experience, KOL advocacy, Spain and Italy. peer-to-peer exchange and awareness in Germany. ✓ National Guideline updates in Germany,
Slide 11: Our potential
OUR POTENTIAL NEXT STEP VALUE DRIVERS Reignited effort in USA with OPD5. Pipeline assets A high global unmet medical need creates sales potential: Pepaxti in rest of ✓ Japan partnership discussion progressing. ✓ South Korea moving ahead. the world ✓ China still being assessed. PEPAXTI IN EUROPE Mark
Slide 12: Update on Japan
UPDATE ON JAPAN Negotiations with potential partner is progressing. Alignment with PMDA – Regulatory Agency. Confirmed high unmet need by Japanese KOLs. 12
Slide 13: European commercialization update
EUROPEAN COMMERCIALIZATION UPDATE 13
Slide 14: European commercialization update
EUROPEAN COMMERCIALIZATION UPDATE 1 2 3 4 Marketing Value Dossier and Cost effectiveness Price negotiations Regional access Healthcare Authorization KOL engagement benefit discussion professional uptake Under assessment: Finland, Denmark, UK, Central & Eastern Europe Germany includes reactive opport
Slide 15: European commercialization update
EUROPEAN COMMERCIALIZATION UPDATE • More than 400 patients treated since EMA approval in 2022. • Sales in all key markets since Q1 2025. 15
Slide 16: European commercialization update
EUROPEAN COMMERCIALIZATION UPDATE • More than 400 patients treated since EMA approval in 2022. • Sales in all key markets since Q1 2025. Q1 2023 Q1 2024 Q1 2025 Accumulated total sales, by end of quarter. 16
Slide 17: Italy – first sales and regional access status ahead of plan
ITALY – FIRST SALES AND REGIONAL ACCESS STATUS AHEAD OF PLAN • Reimbursement decision and first sales already in Q1. • More than 70% of regions access unlocked at hospital level year to date. 17
Slide 18: Italy – first sales and regional access status ahead of plan
ITALY – FIRST SALES AND REGIONAL ACCESS STATUS AHEAD OF PLAN • Reimbursement decision and first sales already in Q1. • More than 70% of regions access unlocked at hospital level year to date. Q1 2025 Accumulated total sales, by end of quarter 18
Slide 19: Italy – first sales and regional access status ahead of plan
ITALY – FIRST SALES AND REGIONAL ACCESS STATUS AHEAD OF PLAN • Reimbursement decision and first sales already in Q1. • More than 70% of regions access unlocked at hospital level year to date. May 14, 2025 Q1 2025 Accumulated total sales, by end of quarter Accumulated total sales, YTD 19
Slide 20: Spain – first sales achieved in 95% of regions in record time
SPAIN – FIRST SALES ACHIEVED IN 95% OF REGIONS IN RECORD TIME • Regional access close to complete with 95%. • Actualidad Económica: “100 Best Ideas of the Year”. 20
Slide 21: Spain – first sales achieved in 95% of regions in record time
SPAIN – FIRST SALES ACHIEVED IN 95% OF REGIONS IN RECORD TIME • Regional access close to complete with 95%. • Actualidad Económica: “100 Best Ideas of the Year”. Q2 2024 Q3 2024 Q4 2024 Q1 2025 Accumulated total sales, by end of quarter 21
Slide 22: Germany – positive experience leads to peer-to-peer recommendations
GERMANY – POSITIVE EXPERIENCE LEADS TO PEER-TO-PEER RECOMMENDATIONS • Strong and growing demand in Germany continues into 2025. • Continued focus on peer-to-peer exchange. 22
Slide 23: Germany – 20% increase in number of prescribers in Q1-25 vs Q4-24
GERMANY – 20 % INCREASE IN NUMBER OF PRESCRIBERS IN Q1 -25 VS Q4 -24 Cumulative number of Pepaxti prescribers in Germany Q4-22 Q1-23 Q2-23 Q3-23 Q4-23 Q1-24 Q2-24 Q3-24 Q4-24 Q1-25 23
Slide 24: Germany – positive experience leads to peer-to-peer recommendations
GERMANY – POSITIVE EXPERIENCE LEADS TO PEER-TO-PEER RECOMMENDATIONS Q1 2025 Q1 2023 Q1 2024 Accumulated total sales, by end of quarter 24
Slide 25: Pipeline assets
PIPELINE ASSETS PDC: Building onto our existing innovation Targets cancer by capitalizing on the metabolic differences between healthy cells and cancer cells while maintaining the patient's quality of life through less side effects. • Now: Potential: improved risk/benefit profile and enhanced intell
Slide 26: The importance of real-world experience
THE IMPORTANCE OF REAL-WORLD EXPERIENCE Three recent publications based on U.S., Italian and Spanish data* indicating strong effectiveness as well as manageable safety, supporting our Trinity concept. “Importantly, the outcomes align with the results of Overall Response Rate 55% in U.S dataset1 our
Slide 27: Challenges in advanced multiple myeloma
Challenges in EFFICACY advanced DIMINISHING TREATMENT OPTIONS multiple myeloma QUALITY SAFETY OF LIFE DECREASING DECLINING QUALITY TOLERABILITY OF LIFE 27
Slide 28: Questions & Answers
28 Questions & Answers © oncopeptides
Slide 29: Bringing hope through science
Bringing hope through science © oncopeptides